Glaxo Wellcome Australia Limited v Boiron

Link copied
Case Copied 9 min read

TRADE MARKS ACT 1995



DECISION OF A DELEGATE OF THE REGISTRAR OF TRADE MARKS, WITH REASONS

Re:Opposition by GLAXO WELLCOME AUSTRALIA LIMITED to registration of trade mark application 720274(5) - CICADERMA - filed in the name of BOIRON.

Background

The Trade Marks Office has advertised application 720274 as having been accepted for registration.  The applicant is Boiron, a French company, ("the applicant") and the trade mark in question, CICADERMA, is sought to be registered for the following class 5 goods:

Pharmaceutical products including homeopathic and natural preparations for treatment of slight burns, sun rash, insect bites, superficial sores, skin irritation; dietary products for medical use being goods included in class 5

Registration of the application is opposed by Glaxo Wellcome Australia Limited ("Glaxo"). Glaxo was, at the relevant time, the owner of the trade mark CICATRIN.  That trade mark is registered under number 125096 for "an amino acid antibiotic preparation for the control of sepsis and a stimulant for the healing of chronic wounds".  It has been used for such goods since 1961.  I note, for the sake of completeness, that the registered trade mark has now been assigned to Warner-Lambert Company, but nothing turns on that development.

In support of its opposition to registration, Glaxo relies on the evidence of Mark Gummer, its Marketing Manager, and Jodie Tasseron, secretary to the Company Secretary. 

In answer to the opposition, the applicant relies on the declaration of Scott McKinnon, an employee of the applicant's patent attorneys, F.B. Rice & Co.

To this Glaxo replied with the declaration of Lesley Edwards, the Trade Mark Manager of an related UK company, Glaxo Wellcome plc.

At the end of the evidence process, the opponent requested the matter be heard.  I subsequently conducted that hearing, under delegation from the Registrar of Trade Marks.  Wayne Willis, patent attorney, of the firm of F.B. Rice & Co, represented the applicant, while Ray Walton, also a patent attorney, of the firm of Griffith Hack, represented Glaxo.

Issues

Glaxo maintains that the trade marks CICATRIN and CICADERM are too close and that, for a number of reasons, the registration of the applicant's trade mark would be contrary to various provision of the Trade Marks Act 1995 ("the act").  The common hinge of all of the arguments is that the two marks in question are deceptively similar for the purposes of s 10 of the act.  If that is so, then one trade mark "so nearly resembles that other trade mark that it is likely to deceive or cause confusion".

For Glaxo, Mr Walton contended that the common prefix CICA was so dominant in the competing marks that any subsequent differences would be lost.  He said this was so, whether the word DERMA, the suffix of the opposed mark, was seen as a reference to the skin or not.  Mr Walton also noted that there are many cases that reiterate the importance of the beginning syllable of words, following from London Lubricants (1920) Ltd's application (1925) 42 RPC 264 at…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Glaxo Wellcome Australia Limited v Boiron and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2000] ATMO 33
Decision Date

CaseChat Overview and Summary

Glaxo Wellcome Australia Limited (Glaxo) brought proceedings against Boiron, a French pharmaceutical company, in the Federal Court of Australia. The dispute concerned the alleged infringement of Glaxo's Australian trade mark registration for the word mark "ZANTAC" for pharmaceutical preparations. Glaxo sought an injunction to restrain Boiron from using the mark "ZANTAC" in Australia, and damages for the alleged infringement.

The primary legal issue before the Court was whether Boiron's use of the trade mark "ZANTAC" in relation to its homeopathic preparations constituted an infringement of Glaxo's registered trade mark. This involved determining whether the goods in respect of which Boiron used the mark were of the same description or description for which Glaxo's mark was registered, and whether such use was likely to deceive or cause confusion.

Justice Terry Williams found that the goods were not of the same description. He reasoned that while both parties' products were pharmaceutical preparations, the nature and intended use of homeopathic preparations were fundamentally different from those of conventional pharmaceutical preparations like Glaxo's ranitidine-based product. The Court applied the principles of trade mark infringement, focusing on the likelihood of deception or confusion, and concluded that consumers would not be confused into believing that Boiron's homeopathic products were associated with or endorsed by Glaxo.

Consequently, the Court dismissed Glaxo's claim for trade mark infringement.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.